Filing Flows › Rafael Holdings (RFL) › Guidance & outlook
Rafael Holdings (RFL) guidance and outlook
Rafael Holdings' 10-K filed Oct 29, 2026 makes 8 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-K filed Oct 29, 2026
- Going forward, we expect that Barer will primarily operate as an entity holding interest in these two cancer-focused opportunities.
- We completed an analysis pursuant to ASC 360 and determined that the expected undiscounted cash flows of the asset group exceeded its carrying amount, indicating that the long-lived assets were not impaired.
- We expect to incur significant expenses in connection with our ongoing activities to support FDA’s review of our NDA for Trappsol® Cyclo™, submitted on October 28, 2026, and, if approved, to commercialize Trappsol® Cyclo™.
- While we are actively pursuing additional financing, there can be no assurance that such funding will be available on acceptable terms, or at all.
- We do not anticipate paying dividends on our common stock unless and until we achieve sustainable profitability and retain certain minimum cash reserves.
- The payment of dividends in any specific period will be at the sole discretion of our Board of Directors.
- The fair value of identifiable intangible assets, in-process research and development (“IPR&D”) and customer relationships, is based on detailed valuations that use information and assumptions provided by management, including expected future cash flows.
- Accordingly, we completed an analysis pursuant to ASC 360 and determined that the expected undiscounted cash flows of the asset group exceeded its carrying amount, indicating that the long-lived assets were not impaired.
Rafael Holdings' latest quarter
Rafael Holdings, Q4 FY26: revenue $244K (-30% year over year), net loss $8.9M, operating cash flow −$8.4M. The chart follows the revenue to costs, profit and cash.
Questions
What does Rafael Holdings expect?
Going forward, we expect that Barer will primarily operate as an entity holding interest in these two cancer-focused opportunities. We completed an analysis pursuant to ASC 360 and determined that the expected undiscounted cash flows of the asset group exceeded its carrying amount, indicating that the long-lived assets were not impaired. We expect to incur significant expenses in connection with our ongoing activities to support FDA’s review of our NDA for Trappsol® Cyclo™, submitted on October 28, 2026, and, if approved, to commercialize Trappsol® Cyclo™.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.